NeuroOne CBO David Wambeke buys $66,999 in company stock
NeuroOne Medical Technologies Corp (NASDAQ:NMTC) CBO David Wambeke bought 33,333 shares for $66,999 at $2.00-$2.017 each. The stock has since fallen to $1.62, down 68% in six months. Wambeke also acquired options for 35,000 shares. NeuroOne reported a 16% revenue increase to $2.0M in Q3, driven by a 43% surge in OneRF product orders, but faced wider losses.
How this was made
The 30-second read
Why it matters
The insider purchase adds a modest positive signal, but the overall company outlook remains mixed due to financial challenges.
Market read
Primary relevance is the insider purchase; broader market impact is minimal.
What to watch
Recent revenue growth may be offset by widening losses and cash constraints.
Background
Article combines insider transaction details with a brief recap of NMTC's Q3 revenue increase and recent share price decline.
Ticker impact
CBO David Wambeke bought 33,333 shares of NeuroOne Medical Technologies (NMTC) for $66,999, disclosed in the article.
Minimal short‑term move; potential slight upside if market views insider buying positively.
Purchase represents less than 0.1% of float and occurs after a recent price decline, so any effect is likely muted.
Market effects
None significant; NeuroOne operates in niche medical‑technology space.
No broader regional effect.
Limited to NMTC investors.
Counterpoint
Insider buying could be a tactical move unrelated to fundamentals.
Key entities
- companyNeuroOne Medical Technologies Corp
NASDAQ‑listed medical‑technology firm (ticker NMTC).
- executiveDavid J. Wambeke
Chief Business Officer of NeuroOne who made the disclosed stock purchase.
